These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3323908)

  • 1. Initial clinical studies of piritrexim.
    Laszlo J; Brenckman WD; Morgan E; Clendeninn NJ; Williams T; Currie V; Young C
    NCI Monogr; 1987; (5):121-5. PubMed ID: 3323908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase.
    Sigel CW; Macklin AW; Woolley JL; Johnson NW; Collier MA; Blum MR; Clendeninn NJ; Everitt BJ; Grebe G; Mackars A
    NCI Monogr; 1987; (5):111-20. PubMed ID: 3431588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre 12-week open study of a lipid-soluble folate antagonist, piritrexim in severe psoriasis.
    Perkins W; Williams RE; Vestey JP; Tidman MJ; Layton AM; Cunliffe WJ; Saihan EM; Klaber MR; Manna VK; Baker H
    Br J Dermatol; 1993 Nov; 129(5):584-9. PubMed ID: 8251356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriasis with piritrexim, a lipid-soluble folate antagonist.
    Guzzo C; Benik K; Lazarus G; Johnson J; Weinstein G
    Arch Dermatol; 1991 Apr; 127(4):511-4. PubMed ID: 2006875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule.
    Adamson PC; Balis FM; Miser J; Arndt C; Wells RJ; Gillespie A; Aronson L; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1992 Feb; 52(3):521-4. PubMed ID: 1732038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.
    Stuart NS; Crawford SM; Blackledge GR; Newlands ES; Slack J; Hoffman R; Stevens MF
    Cancer Chemother Pharmacol; 1989; 23(5):308-10. PubMed ID: 2706736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.
    de Vries EG; Gietema JA; Workman P; Scott JE; Crawshaw A; Dobbs HJ; Dennis I; Mulder NH; Sleijfer DT; Willemse PH
    Br J Cancer; 1993 Sep; 68(3):641-4. PubMed ID: 8353055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.
    Bleehen NM; Newman HV; Rampling RP; Ramsay JR; Roberts JT; Bedford P; Nethersell AB
    Br J Cancer; 1995 Sep; 72(3):766-8. PubMed ID: 7669591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The disposition and metabolism of [14C]piritrexim in rats after intravenous and oral administration.
    Woolley JL; Deangelis DV; Crouch RC; Shockcor JP; Sigel CW
    Drug Metab Dispos; 1991; 19(3):600-8. PubMed ID: 1680625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
    Lassiter LK; Tummala MK; Hussain MH; Stadler WM; Petrylak DP; Carducci MA
    Clin Genitourin Cancer; 2008 Mar; 6(1):31-5. PubMed ID: 18501080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of 10-deaza-aminopterin in patients with advanced cancer.
    Currie VE; Warrell RP; Arlin Z; Tan C; Sirotnak FM; Greene G; Young CW
    Cancer Treat Rep; 1983 Feb; 67(2):149-54. PubMed ID: 6825121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration.
    Feun LG; Gonzalez R; Savaraj N; Hanlon J; Collier M; Robinson WA; Clendeninn NJ
    J Clin Oncol; 1991 Mar; 9(3):464-7. PubMed ID: 1999717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U).
    Weiss GR; Sarosy GA; Shenkenberg TD; Williams T; Clendeninn NJ; Von Hoff DD; Woolley JL; Liao SH; Blum MR
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1867-73. PubMed ID: 2632268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral piritrexim--a phase II study in patients with advanced soft tissue sarcoma.
    Schiesel JD; Carabasi M; Magill G; Casper E; Cheng E; Marks L; Feyzi J; Clendeninn NJ; Smalley RV
    Invest New Drugs; 1992 Jul; 10(2):97-8. PubMed ID: 1500271
    [No Abstract]   [Full Text] [Related]  

  • 16. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule.
    Adamson PC; Balis FM; Miser J; Wells RJ; Bleyer WA; Williams TE; Gillespie A; Penta JS; Clendeninn NJ; Poplack DG
    Cancer Res; 1990 Aug; 50(15):4464-7. PubMed ID: 2369724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
    Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
    Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
    Feun LG; Savaraj N; Benedetto P; Hanlon J; Sridhar KS; Collier M; Richman S; Liao SH; Clendeninn NJ
    J Natl Cancer Inst; 1991 Jan; 83(1):51-5. PubMed ID: 1984518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.